Update: Effect of thrombolysis in acute ischemic stroke

Annals of Emergency Medicine

Volumn 57, Issue 3, 2011, Pages

  Mitchell, Jason ^a   Lang, Eddy ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DRUG SAFETY; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); MORTALITY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RISK BENEFIT ANALYSIS; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 79952018958     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2010.08.015     Document Type: Editorial

References (12)

1. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Hacke W, Kaste M, Fieschi C, et al, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
4. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251. (Pubitemid 28470336)
5. Clark WM, Albers GW, Madden KP, et al. The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0267g): results of a double-blind, placebo-controlled, multicenter study. Stroke. 2000;31:811-816. (Pubitemid 30198420)
6. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study - a randomized controlled trial, JAMA. 1999;282:2019-2026.
7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
8. Sandercock P, Lindley R, Wardlaw J, et al. Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials. 2008;9:37.
9. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369: 275-282. (Pubitemid 46138121)
10. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150. (Pubitemid 30126602)
11. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172:1307-1312. (Pubitemid 40745072)
12. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303-1309.